Simris Group AB

SIMRIS B

SE0008091664

Food Processing

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
0.15 ^SEK	0.00%		-7.98%	-33.33%

Jun. 28	Simris Group AB Appoints Jonathan Royce as Members of the Board	CI
May. 27	Simris Group AB Announces Robert Quandt Declines Re-Election as Member of Board	CI

SIMRIS ALG: Video Interview with SIMRIS CEO Julian Read and CYANO BIOTECH Co-Founder Dan Enke

September 07, 2022 at 05:31 am EDT

In the interview CEO Julian Read discusses
- Why Simris has acquired Berlin-based cyanobacteria firm CYANO BIOTECH
- His plan for SIMRIS' entry into the biopharma space
- The outlook for SIMRIS' revenue distribution in 2023 and long term
- His top priorities as CEO for the next 12 months

Also hear CYANO BIOTECH Co-Founder Dan Enke discuss why cyanobacteria is such a good fit as payload in the emerging ADC cancer treatments.

See the video interview here https://youtu.be/pl_fX21izFg
Also read our research report on SIMRIS here https://www.emergers.se/simris_m/

About Emergers

This is a press release from Emergers.

DISCLAIMER
Information provided here or on Emergers' website emergers.se is not intended to be financial advice. Emergers receives compensation for writing about the company in question. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers' own. Articles of analysis shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot guarantee that the conclusions presented in the analysis will be met. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.

For more information and complete terms, please see emergers.se.

Latest news about Simris Group AB

Simris Group AB Appoints Jonathan Royce as Members of the Board	Jun. 28	CI
Simris Group AB Announces Robert Quandt Declines Re-Election as Member of Board	May. 27	CI
Simris Group AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Simris Group AB Enters into Amended Agreement to Extend the Term of the Flexible Funding Facility with The Brand Laboratories FZ	Apr. 15	CI
Simris Group AB announced that it expects to receive ?1.15 million in funding from The Claremont Trust, Mountain High Trust, The Brand Laboratories FZE and other investors	Mar. 13	CI
Simris Group AB Announces CEO Changes	Mar. 12	CI
Simris Group AB Resolves to Temporarily Pause Production Operations At Its Microalgae Facility in Hammenhög, Sweden	Mar. 06	CI
Simris Group AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Simris Group AB Signs Head of Terms for an Offtake Agreement Valued At Minimum ?2 Million / SEK 22 Million	Jan. 10	CI
Simris Group AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Simris Appoints Reviate LLC as Exclusive Distributor	Nov. 07	CI
Simris Group AB announced that it has received SEK 2.9295 million in funding	23-10-29	CI
Simris Group AB Confirms New Patent Application from Its Adc-Payload Platform	23-08-02	CI
Simris Group AB Announces Executive Changes	23-07-28	CI
Simris Group AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-24	CI
Simris Group AB announced that it expects to receive SEK 2.9295 million in funding	23-05-28	CI
Simris Alg AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Simris Group AB Broadens Distribution of Its Reformulated Algal Omega-3 Products	23-04-28	CI
Simris Alg AB Auditor Raises 'Going Concern' Doubt	23-04-16	CI
Simris Alg AB Enters into Bridge Loan Agreement with the Brand Laboratories FZ	23-03-06	CI
Simris Alg AB has Changed its Name to Simris Group AB	23-03-06	CI
Simris Alg AB Signs Partnership Agreement with Lonza Ltd to Promote its ADC Payload Technology	23-02-28	CI
Simris Alg AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Simris Alg AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Simris Alg AB (OM:SIMRIS B) acquired 100% of the shares in Cyano Biotech GmbH.	22-08-24	CI

Chart Simris Group AB

Duration

Period

More charts

Company Profile

Simris Alg AB is a Sweden-based company, which is primarily engaged in the special foods and wellbeing products industry. The Company operates as a manufacturer of dietary supplements and specialty foods. The Company's products are based on algae-plants that live in water, such as seaweed, phytoplankton and kelp. These products are rich of Omega-3 oils and made from natural ingredients. The Company offers a wide range of algae-based supplements and foods, among them are Simris Algae Omega-3 Original, Simris Algae Omega-3 for Mothers, Simris Algae Omega-3 for Athletes, Finest Chlorella, Sundried Spirulina, Boosting Astaxanthin, Chlorella Crispies, Flower Power Algae Tea, Sun Candy Algae Tea and other.

Sector

Food Processing

Calendar

2024-08-13 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
SIMRIS GROUP AB	-33.33%	4.97M
ZHEJIANG NHU COMPANY LTD.	+13.33%	8.17B
BELLRING BRANDS, INC.	+6.62%	7.71B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	-19.26%	4.44B
THE SIMPLY GOOD FOODS COMPANY	-8.54%	3.59B
BYHEALTH CO., LTD	-20.61%	3.14B
XIAMEN KINGDOMWAY GROUP COMPANY	-12.55%	1.2B
HERBALIFE LTD.	-26.47%	1.14B
JAMIESON WELLNESS INC.	-7.63%	888M
USANA HEALTH SCIENCES, INC.	-17.95%	857M